Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

As part of a collaboration agreement signed in 2019, Sarepta is working with Roche (RHHBY) to transform the future for the Duchenne community, enabling those living with the disease to maintain ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Roche Holding AG (RHHVF – Research Report). Sarepta ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene moxeparvovec) as a gene therapy for treating Duchenne ...

No new safety signals were observed. As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is responsible for regulatory approval and ...

Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

Sarepta already markets three exon-skipping drugs for DMD that have to be taken chronically, but SRP-9001 offers the possibility of a one-shot therapy for the disease. Roche has exclusive rights ...

In 2019, Roche entered into a global collaboration agreement with Sarepta Therapeutics, Inc. to commercialise Elevidys in territories outside the US. Study 101 (NCT03375164), a phase I/II study ...

Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained ...